64,822 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Acquired by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 64,822 shares of the company’s stock, valued at approximately $935,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in ELAN. ORG Partners LLC purchased a new stake in shares of Elanco Animal Health during the second quarter valued at $31,000. nVerses Capital LLC purchased a new stake in Elanco Animal Health during the 2nd quarter valued at about $32,000. Jones Financial Companies Lllp acquired a new position in shares of Elanco Animal Health in the fourth quarter valued at about $37,000. Global Financial Private Client LLC purchased a new position in shares of Elanco Animal Health in the first quarter worth about $72,000. Finally, Meeder Advisory Services Inc. acquired a new stake in shares of Elanco Animal Health during the second quarter worth about $154,000. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 6.6 %

ELAN stock opened at $14.07 on Friday. Elanco Animal Health Incorporated has a one year low of $8.52 and a one year high of $18.80. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.75 and a current ratio of 2.93. The firm’s fifty day moving average is $13.95 and its 200 day moving average is $15.15. The firm has a market cap of $6.95 billion, a PE ratio of -5.31, a P/E/G ratio of 1.44 and a beta of 1.40.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the company posted $0.18 EPS. The company’s revenue for the quarter was up 12.0% on a year-over-year basis. On average, research analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price target on shares of Elanco Animal Health in a report on Thursday. Barclays reduced their target price on shares of Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, June 28th. Piper Sandler lowered their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st. Finally, Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and reduced their price objective for the company from $17.00 to $15.00 in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $17.29.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 100,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were purchased at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the transaction, the chief executive officer now directly owns 145,000 shares of the company’s stock, valued at approximately $1,886,450. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Michael J. Harrington acquired 3,500 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was bought at an average cost of $14.85 per share, for a total transaction of $51,975.00. Following the purchase, the director now owns 81,094 shares in the company, valued at $1,204,245.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jeffrey N. Simmons bought 100,000 shares of the firm’s stock in a transaction dated Monday, August 12th. The stock was purchased at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the transaction, the chief executive officer now owns 145,000 shares of the company’s stock, valued at $1,886,450. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.